About this item:

243 Views | 187 Downloads

Author Notes:

Address correspondence to: Martin A. Schwartz, Yale Cardiovascular Research Center, 300 George St., 7th floor, New Haven, Connecticut 06511, USA. Email: martin.schwartz@yale.edu

SY and MAS designed the project. SY, RH, MES, ANS, and ZZ conducted the experiments and analyzed the data. SY and MAS generated the figures and wrote the manuscript. AJK and DCP provided technical advice and edited the manuscript. MAS directed and supervised the project.

We thank Jiasheng Zhang (Yale University) for assistance with mouse femoral artery ligation (FAL) surgery and Stefano Piccolo (University of Padova, Italy) for providing Flag-Yap DNA and for critical comments on the manuscript.

We are grateful to Rita Webber, Nicole Copeland, and Laran Coon for maintaining the mouse colonies used in this study.

The authors have declared that no conflict of interest exists.

Subject:

Research Funding:

Lipid analysis was done by the Yale Mouse Phenotypic Center, which is supported by NIH grant U24 DK059635.

This work was funded by NIH grants 5R01HL75092, RO1 HL135582, and PO1107205 (to MAS) and R01s MH115939, NS105640, and NS089662 (to AJK).

Keywords:

  • Science & Technology
  • Life Sciences & Biomedicine
  • Medicine, Research & Experimental
  • Research & Experimental Medicine
  • KAPPA-B ACTIVATION
  • REDUCES ATHEROSCLEROSIS
  • FIBRONECTIN DEPOSITION
  • IN-VIVO
  • PROTEIN
  • ANGIOGENESIS
  • EXPRESSION
  • YAP/TAZ
  • GROWTH
  • FLOW

Integrin alpha 5 beta 1 regulates PP2A complex assembly through PDE4D in atherosclerosis

Tools:

Journal Title:

JOURNAL OF CLINICAL INVESTIGATION

Volume:

Volume 129, Number 11

Publisher:

, Pages 4863-4874

Type of Work:

Article | Final Publisher PDF

Abstract:

Fibronectin in the vascular wall promotes inflammatory activation of the endothelium during vascular remodeling and atherosclerosis. These effects are mediated in part by fibronectin binding to integrin α5, which recruits and activates phosphodiesterase 4D5 (PDE4D5) by inducing its dephosphorylation on an inhibitory site, S651. Active PDE then hydrolyzes antiinflammatory cAMP to facilitate inflammatory signaling. To test this model in vivo, we mutated the integrin binding site of PDE4D5 in mice. This mutation reduced endothelial inflammatory activation in atherosclerosis-prone regions of arteries and, in a hyperlipidemia model, reduced atherosclerotic plaque size while increasing markers of plaque stability. We then investigated the mechanism of PDE4D5 activation. Proteomics identified the PP2A regulatory subunit B55α as the factor recruiting PP2A to PDE4D5. The B55α-PP2A complex localized to adhesions and directly dephosphorylated PDE4D5. This interaction also, unexpectedly, stabilized the PP2A-B55α complex. The integrin-regulated, proatherosclerotic transcription factor Yap was also dephosphorylated and activated through this pathway. PDE4D5 therefore mediated matrix-specific regulation of endothelial cell phenotype via an unconventional adapter role, assembling and anchoring a multifunctional PP2A complex that has other targets. We believe these results may have widespread consequences for the control of cell function by integrins.

Copyright information:

Copyright: © 2019, American Society for Clinical Investigation.

Export to EndNote